Pluripotent Stem Cell Differentiation for Hematopoietic Progenitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing the differentiation of human pluripotent stem cells into hematopoietic progenitor cells are inefficient, time-consuming, and often require serum-containing systems, which are unsuitable for clinical-grade cell formulations, while existing sources of hematopoietic stem cells are limited and unstable.
Innovation Solution
A method involving a series of culture steps using ROCK and GSK-3β inhibitors, along with specific growth factors and cytokines, to differentiate pluripotent stem cells into hematopoietic progenitor cells in a serum-free and chemically defined environment, including embryoid body, mesoderm, hemogenic endothelium, and hematopoietic progenitor cell cultures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If embryoid body differentiation method is used, then hematopoietic progenitor cells can be generated, but differentiation efficiency is low and time consumption is excessive
Solution Approach 1:
The differentiation process is divided into four distinct sequential stages: embryoid body formation, mesoderm differentiation, hemogenic endothelium differentiation, and hematopoietic progenitor cell differentiation. Each stage uses specific culture conditions and growth factors to efficiently guide cells through defined developmental transitions, avoiding the time-consuming and inefficient single-step approaches of conventional methods.
Solution Approach 2:
The method performs preliminary actions by first forming embryoid bodies from pluripotent stem cells, then systematically guiding them through mesoderm and hemogenic endothelium stages before final differentiation into hematopoietic progenitor cells. This staged preliminary preparation ensures efficient and controlled differentiation, significantly reducing overall time consumption compared to direct differentiation approaches.
2Productivity
If stromal cell co-incubation method is used, then hematopoietic progenitor cells can be generated, but efficiency is unstable and animal-derived components are introduced
Solution Approach 1:
The method extracts and eliminates stromal cells and animal-derived components from the differentiation system. Instead of relying on stromal cell co-incubation, the protocol uses a serum-free, chemically-defined culture system with specific growth factors (BMP4, VEGF, FGF2, SCF) that independently drive hematopoietic differentiation, ensuring stable and reliable efficiency without animal-derived contaminants.
Solution Approach 2:
The method changes the cultural parameters by transitioning from serum-containing systems to a serum-free, chemically-defined medium system. By precisely controlling the concentration and timing of specific growth factors (BMP4 at 10-50 ng/mL, VEGF at 10-50 ng/mL, FGF2 at 10-50 ng/mL, SCF at 10-50 ng/mL), the protocol achieves stable and reliable differentiation efficiency while eliminating animal-derived components.
3Quantity of substance
If conventional HSC sources (cord blood, bone marrow, peripheral blood) are used, then hematopoietic stem cells can be obtained, but sources are limited and match efficiency is low
Solution Approach 1:
The method creates laboratory-generated hematopoietic progenitor cells that copy and replicate the functional characteristics of clinical HSC sources. These in vitro-generated cells possess similar differentiation potential and hematopoietic capabilities, providing an unlimited and versatile source that can be produced on-demand without the limitations of donor availability and HLA matching associated with conventional HSC sources.
4Reliability
If autologous HSC transplantation is used, then graft rejection and graft-versus-host disease are avoided, but autologous HSC shortage in cord blood banks limits clinical applications
Solution Approach 1:
The method enables self-service by allowing pluripotent stem cells to differentiate into hematopoietic progenitor cells through a controlled in vitro process. This self-differentiation capability provides an on-demand source of hematopoietic cells that can be used for patient transplantation without relying on scarce autologous HSCs in cord blood banks, while maintaining graft compatibility by using the patient's own stem cell lineage.
Data Source
AI summary
The present disclosure relates to a method for induced differentiation of stem cells into hematopoietic progenitor cells. The method comprises the following steps: culturing pluripotent stem cells to obtain an embryoid body; performing mesoderm differentiation culture on the embryoid body to obtain mesoderm cells; performing hemogenic endothelium differentiation culture on the mesoderm cells to obtain hemogenic endothelial cells; and performing hematopoietic progenitor cell differentiation culture on the hemogenic endothelial cells to obtain hematopoietic progenitor cells. According to the present disclosure, the hematopoietic progenitor cells can be rapidly and efficiently prepared, and the prepared hematopoietic progenitor cells have an ability to stably differentiate into a plurality of different blood cells (including simultaneously having erythroid, myeloid, and lymphoid cells); by optimizing a culture system, the differentiation efficiency is significantly improved and the number of hematopoietic progenitor cells obtained is significantly increased.